Candidemia in the neonatal intensive care unit

Area of Science:

• Neonatal Medicine
• Infectious Diseases
• Mycology

Background:

• Candidemia is an emerging threat in neonatal intensive care units (NICUs).
• Recent increases in cases highlight the need to understand its characteristics and outcomes.
• The mortality rate in this study was 56%, indicating a severe clinical challenge.

Purpose of the Study:

• To retrospectively analyze the characteristics, associated factors, and treatment outcomes of candidemia in neonates.
• To identify risk factors and common clinical presentations of Candida bloodstream infections in the NICU.
• To evaluate the effectiveness of amphotericin B treatment in this vulnerable population.

Main Methods:

• Retrospective review of hospital records for 18 infants with positive Candida blood cultures.
• Analysis of patient demographics, clinical presentations, associated factors, and antifungal treatment regimens.
• Comparison of treatment outcomes based on the adequacy of amphotericin B dosing.

Main Results:

• Candida albicans was the most common species (16/18 cases), followed by Candida parapsilosis (2/18 cases).
• Common presentations included fever, lethargy, and abdominal distention, often mimicking bacterial sepsis or necrotizing enterocolitis.
• Eleven associated factors were identified, primarily related to NICU interventions like prolonged broad-spectrum antibiotics and parenteral nutrition.
• All patients received intravenous amphotericin B; however, 12 received inadequate doses (< 25 mg/Kg), and all 10 fatalities occurred in this group.

Conclusions:

• Candidemia is a significant and increasing problem in NICUs, associated with high mortality.
• Inadequate dosing of amphotericin B is strongly correlated with fatal outcomes.
• Neonatal candidemia requires prompt recognition, appropriate diagnostic evaluation, and effective antifungal therapy, including adequate dosing.